Trends in Parathyroid Hormone Plasma Concentration in Multi-organ Failure Critically Ill Patients Undergoing Regional Citrate Anticoagulation Continuous Renal Replacement Therapies - Prospective Observational Study.
| Registry | NCT03873675 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 30 (Actual) |
| Sponsor | Uniwersytecki Szpital Kliniczny w Opolu (Other) |
| Conditions | Critical Illness, Multi Organ Failure, Renal Failure, Circulatory Failure, Respiratory Failure |
| Interventions | parathyroid hormone (Diagnostic test) |
| Dates | start 2019-05-06, primary completion 2020-10-01, completion 2020-11-01, first posted 2019-03-13, last updated 2022-01-14 |
| Locations | 3 sites in Poland |
Related Papers Related Patents Related Grants Related Experts
All trials for Critical Illness All trials for Multi Organ Failure All trials of parathyroid hormone
The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation continuous renal replacement therapy.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Study group | Diagnostic Test: parathyroid hormone | Multi-organ failure with acute kidney injury critically ill patients admitted to the intensive care unit undergoing regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF). Multi-organ failure is defined as a respiratory, circulatory and renal failure. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Acute respiratory failure * Acute circulatory failure * acute kidney injury treated with regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF * continuous renal replacement therapy started no later than 48 hours after admission * SOFA score 5 or more Exclusion Criteria: * age less than 18 years * acute liver failure * hypercalcemia at admission (total calcium plasma level > 10.6 mg/dL; total ionized calcium plasma level > 1.35 mmol/L * parathyroid glands disease * end stage renal disease * therapeutic plasma exchange * extracorporeal membrane oxygenation * unfavorable outcome (death) predicted within 72 hours (as assessed by investigator) * lack of relatives consent
| Facility | City | Country | Status |
|---|---|---|---|
| Department of Endocrinology, Diabetology and Isotope Therapy, Wroclaw Medical University, Poland. | Wroclaw, Lower Silesian Voivodeship | Poland | |
| Department of Endocrinology, Szpital Wojewodzki w Opolu | Opole, Silesian Voivodeship | Poland | |
| Department of Anesthesiology and Intensive Care, Uniwersytecki Szpital Kliniczny w Opolu | Opole, Silesian Voivodeship | Poland |